abiraterone has been researched along with Breast Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrahamsson, M; Falkenius, J; Henriksson, R; Lindquist, M; Lööv, SÅ; Norin, S; Öhman, D | 1 |
| Dowsett, M; Folkerd, E; Johnston, SR; Liccardi, G; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Ribas, R; Simigdala, N | 1 |
| Capper, CP; Johnson, MD; Larios, JM; Rae, JM; Sikora, MJ | 1 |
| Abderrahman, B; Bhattacharya, P; Fan, P; Hawsawi, YM; Jordan, VC; Maximov, PY; Pokharel, N | 1 |
4 other study(ies) available for abiraterone and Breast Cancer
| Article | Year |
|---|---|
[Register for new drugs in cancer care provides a picture of how the drugs are used in the daily clinical practice].
Topics: Androstenes; Antineoplastic Agents; Benzamides; Bevacizumab; Breast Neoplasms; Colorectal Neoplasms; Drug Utilization; Humans; Ipilimumab; Male; Melanoma; Neoplasms; Nitriles; Palliative Care; Phenylthiohydantoin; Pilot Projects; Prostatic Neoplasms; Radium; Registries; Survival Rate; Sweden; Withholding Treatment | 2017 |
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
Topics: Androstenes; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Receptors, Androgen; Signal Transduction; Tamoxifen | 2018 |
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Proteins; Receptors, Estrogen | 2016 |
Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Quality of Life; Receptors, Estrogen; Survival Rate; Tamoxifen | 2016 |